The degeneration and death of dopaminergic neurons in the mesencephalic substantia nigra leads to insufficient dopamine secretion in the cerebral striatum, which leads to the corresponding clinical manifestations in patients, which is the main pathogenesis of Parkinson's disease. At present, there are two main clinical treatment methods: drug treatment and surgical treatment. However, both treatments have side effects, so it is inevitable to explore new treatment methods for Parkinson's disease. In this review, we discuss the application of stem cells in the treatment of Parkinson's disease, and specifically expand from the acquisition of stem cells, brain transplantation, and in vivo functions. We focus on the great potential of cell therapy in Parkinson's treatment and highlight the potential therapeutic applications of stem cells in clinical medicine.

Yizhou Liu, Yanbin Xue. Stem-cell-based treatment of PD. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 6: 55-60. https://doi.org/10.25236/AJMHS.2024.050608.

[1] Han F, Hu B. Stem Cell Therapy for Parkinson's Disease. Adv Exp Med Biol. 2020; 1266:21-38. doi: 10.1007/978-981-15-4370-8_3. PMID: 33105493.

[2] Zeng X, Couture LA. Pluripotent stem cells for Parkinson’s disease: progress and challenges.Stem Cell Res Ther.2013;4(2):25. doi: 10.1186/scrt173.

[3] Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells.J Clin Invest.2010;120(1):51–9. doi: 10.1172/JCI40553.

[4] Han F, Baremberg D, Gao J, Duan J, Lu X, Zhang N, Chen Q.Development of stem cell-based therapy for Parkinson's disease.Transl Neurodegener.2015 Sep 3;4:16. doi: 10.1186/s40035-015-0039-8. PMID: 26339485; PMCID: PMC4559356.

[5] Kim HJ, McMillan E, Han F, Svendsen CN. Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. Stem Cells. 2009; 27(2):390–8. doi:10.1634/stemcells.2007-1047. 

[6] Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, et al. A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.PLoS One. 2009; 4(8):e6606. doi: 10.1371/journal.pone.0006606.

[7] Berlet Reed, Galang Cabantan Dorothy Anne,Gonzales Portillo Daniel,Borlongan Cesar V.. Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke,Parkinson’s Disease, and Huntington’s Disease[J].Frontiers in Cell and Developmental Biology, 2022,10: 798826.

[8] Parmar Malin,Grealish Shane,Henchcliffe Claire.The future of stem cell therapies for Parkinson disease.[J].Nature reviews.Neuroscience,2020,21(2):103-115.

[9] Department of Cell Biology and Neurosciences,Department of Chemistry and Biochemistry,Montana State University, Bozeman, MT, USA., Department of Cell Biology and Neurosciences,Department of Chemistry and Biochemistry, Montana State University,Bozeman, MT, USA .Stem cell therapy for Parkinson's disease:safety and modeling.[J].Neural regeneration research, 2020,15(1):36-40.

[10] Morizane Asuka, Takahashi Jun. Cell therapy for Parkinson’s disease with induced pluripotent stem cells[J].Glycoforum, 2020, 23(3):A10.

[11] Thompson Cassandra,Otero Paulina,Srinageshwar Bhairavi,Petersen Robert B,Dunbar Gary L,Rossignol Julien.Possible roles of epigenetics in stem cell therapy for Parkinson's disease.[J]. Epigenomics, 2020, 12(7):647-656.

[12] Park T Y, Jeon J, Cha Y, et al. Past, present, and future of cell replacement therapy for parkinson’s disease: a novel emphasis on host immune responses[J]. Cell Research, 2024: 1-14.

[13] Li Y, Glass Z, Huang M, et al. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications[J]. Biomaterials, 2020, 234: 119711.

[14]Yasuhara T, Kawauchi S, Kin K, et al. Cell therapy for central nervous system disorders: current obstacles to progress[J]. CNS neuroscience & therapeutics, 2020, 26(6): 595-602.

[15] Cho Y W, Park J H, Kang M J, et al. Crater-like nanoelectrode arrays for electrochemical detection of dopamine release from neuronal cells[J]. Biomedical Materials, 2023, 18(6): 065015. 

[16] Romano E, Zhang D Q. Dopaminergic amacrine cells express hyperpolarization-activated, cyclic nucleotide-gated channels in the mouse retina[J]. Investigative Ophthalmology & Visual Science, 2023, 64(8): 1642.

[17] Tikhonova M A, Shvaikovskaya A A, Zhanaeva S Y, et al. Concordance between the In Vivo Content of Neurospecific Proteins (BDNF, NSE, VILIP-1, S100B) in the Hippocampus and Blood in Patients with Epilepsy[J]. International Journal of Molecular Sciences, 2023, 25(1): 502.

[18] Hiller B M, Marmion D J, Thompson C A, et al. Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease[J]. NPJ Regenerative medicine, 2022, 7(1): 24.

[19] Studer L. Strategies for bringing stem cell-derived dopamine neurons to the clinic—the NYSTEM trial [J]. Progress in brain research, 2017, 230: 191-212.

[20] Haworth R, Sharpe M. Accept or reject: the role of immune tolerance in the development of stem cell therapies and possible future approaches[J]. Toxicologic Pathology, 2021, 49(7): 1308-1316.

[21] Aramini B, Masciale V, Grisendi G, et al. Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence[J]. Cancers, 2022, 14(4): 976.

[22] Wilson H, de Natale E R, Politis M. Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases[J]. Stem Cells, 2022, 40(8): 724-735.

[23] Zhou Z, Shi B, Xu Y, et al. Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis[J]. Stem Cell Research & Therapy, 2023, 14(1): 3.

[24] Zhang L, Yang H. Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson’s disease[J]. Molecular Biology Reports, 2024, 51(1): 347.

[25] Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: a fundamental biosafety aspect[J]. International journal of molecular sciences, 2019, 20(10): 2406.

[26] Brot S, Thamrin N P, Bonnet M L, et al. Long-term evaluation of intranigral transplantation of human iPSC-derived dopamine neurons in a Parkinson’s disease mouse model[J]. Cells, 2022, 11(10): 1596.

[27] Nishimura K, Takata K. Combination of drugs and cell transplantation: more beneficial stem cell-based regenerative therapies targeting neurological disorders[J]. International journal of molecular sciences, 2021, 22(16): 9047.

[28] Zhang Q, Chen W, Tan S, et al. Stem cells for modeling and therapy of Parkinson's disease[J]. Human gene therapy, 2017, 28(1): 85-98.

[29] Li M, Jiang Y, Hou Q, et al. Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects[J]. Stem cell research & therapy, 2022, 13(1): 146.

[30] Alghwiri A A, Jamali F, Aldughmi M, et al. The effect of stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: A comparative study [J]. Medicine, 2020, 99(34): e21646.

[31] Tian L, Al-Nusaif M, Chen X, et al. Roles of transcription factors in the development and reprogramming of the dopaminergic neurons[J]. International Journal of Molecular Sciences, 2022, 23(2): 845.

[32] Çınar E, Tel B C, Şahin G. Neuroinflammation in parkinson’s disease and its treatment opportunities[J]. Balkan medical journal, 2022, 39(5): 318.

[33] Park J M, Rahmati M, Lee S C, et al. Effects of mesenchymal stem cell on dopaminergic neurons, motor and memory functions in animal models of Parkinson's disease: a systematic review and meta-analysis[J]. Neural Regeneration Research, 2024, 19(7): 1584-1592.

[34] Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies [J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 35.